Search Results - "Pusic, Iskra"

Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement by Herrmann, Joerg, Lenihan, Daniel, Armenian, Saro, Barac, Ana, Blaes, Anne, Cardinale, Daniela, Carver, Joseph, Dent, Susan, Ky, Bonnie, Lyon, Alexander R, López-Fernández, Teresa, Fradley, Michael G, Ganatra, Sarju, Curigliano, Giuseppe, Mitchell, Joshua D, Minotti, Giorgio, Lang, Ninian N, Liu, Jennifer E, Neilan, Tomas G, Nohria, Anju, O'Quinn, Rupal, Pusic, Iskra, Porter, Charles, Reynolds, Kerry L, Ruddy, Kathryn J, Thavendiranathan, Paaladinesh, Valent, Peter

“…Abstract The discipline of Cardio-Oncology has seen tremendous growth over the past decade. It is devoted to the cardiovascular (CV) care of the cancer…”
Get full text

Ibrutinib for chronic graft-versus-host disease after failure of prior therapy by Miklos, David, Cutler, Corey S., Arora, Mukta, Waller, Edmund K., Jagasia, Madan, Pusic, Iskra, Flowers, Mary E., Logan, Aaron C., Nakamura, Ryotaro, Blazar, Bruce R., Li, Yunfeng, Chang, Stephen, Lal, Indu, Dubovsky, Jason, James, Danelle F., Styles, Lori, Jaglowski, Samantha

“…Chronic graft-versus-host disease (cGVHD) is a serious complication of allogeneic stem cell transplantation with few effective options available after failure…”
Get full text

Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study by Cutler, Corey, Lee, Stephanie J., Arai, Sally, Rotta, Marcello, Zoghi, Behyar, Lazaryan, Aleksandr, Ramakrishnan, Aravind, DeFilipp, Zachariah, Salhotra, Amandeep, Chai-Ho, Wanxing, Mehta, Rohtesh, Wang, Trent, Arora, Mukta, Pusic, Iskra, Saad, Ayman, Shah, Nirav N., Abhyankar, Sunil, Bachier, Carlos, Galvin, John, Im, Annie, Langston, Amelia, Liesveld, Jane, Juckett, Mark, Logan, Aaron, Schachter, Levanto, Alavi, Asif, Howard, Dianna, Waksal, Harlan W., Ryan, John, Eiznhamer, David, Aggarwal, Sanjay K., Ieyoub, Jonathan, Schueller, Olivier, Green, Laurie, Yang, Zhongming, Krenz, Heidi, Jagasia, Madan, Blazar, Bruce R., Pavletic, Steven

“…Belumosudil, an investigational oral selective inhibitor of Rho-associated coiled-coil–containing protein kinase 2 (ROCK2), reduces type 17 and follicular T…”
Get full text

TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes by Welch, John S, Petti, Allegra A, Miller, Christopher A, Fronick, Catrina C, O’Laughlin, Michelle, Fulton, Robert S, Wilson, Richard K, Baty, Jack D, Duncavage, Eric J, Tandon, Bevan, Lee, Yi-Shan, Wartman, Lukas D, Uy, Geoffrey L, Ghobadi, Armin, Tomasson, Michael H, Pusic, Iskra, Romee, Rizwan, Fehniger, Todd A, Stockerl-Goldstein, Keith E, Vij, Ravi, Oh, Stephen T, Abboud, Camille N, Cashen, Amanda F, Schroeder, Mark A, Jacoby, Meagan A, Heath, Sharon E, Luber, Kierstin, Janke, Megan R, Hantel, Andrew, Khan, Niloufer, Sukhanova, Madina J, Knoebel, Randall W, Stock, Wendy, Graubert, Timothy A, Walter, Matthew J, Westervelt, Peter, Link, Daniel C, DiPersio, John F, Ley, Timothy J

“…Decitabine produced responses in patients with acute myeloid leukemia or myelodysplastic syndromes who had cytogenetic abnormalities associated with a poor…”
Get full text

Genomic analysis of germ line and somatic variants in familial myelodysplasia/acute myeloid leukemia by Churpek, Jane E., Pyrtel, Khateriaa, Kanchi, Krishna-Latha, Shao, Jin, Koboldt, Daniel, Miller, Christopher A., Shen, Dong, Fulton, Robert, O’Laughlin, Michelle, Fronick, Catrina, Pusic, Iskra, Uy, Geoffrey L., Braunstein, Evan M., Levis, Mark, Ross, Julie, Elliott, Kevin, Heath, Sharon, Jiang, Allan, Westervelt, Peter, DiPersio, John F., Link, Daniel C., Walter, Matthew J., Welch, John, Wilson, Richard, Ley, Timothy J., Godley, Lucy A., Graubert, Timothy A.

“…Familial clustering of myelodysplastic syndromes (MDSs) and acute myeloid leukemia (AML) can be caused by inherited factors. We screened 59 individuals from 17…”
Get full text

Randomized multicenter trial of sirolimus vs prednisone as initial therapy for standard-risk acute GVHD: the BMT CTN 1501 trial by Pidala, Joseph, Hamadani, Mehdi, Dawson, Peter, Martens, Michael, Alousi, Amin M., Jagasia, Madan, Efebera, Yvonne A., Chhabra, Saurabh, Pusic, Iskra, Holtan, Shernan G., Ferrara, James L.M., Levine, John E., Mielcarek, Marco, Anasetti, Claudio, Antin, Joseph H., Bolaños-Meade, Javier, Howard, Alan, Logan, Brent R., Leifer, Eric S., Pritchard, Theresa S., Horowitz, Mary M., MacMillan, Margaret L.

“…Clinical- and biomarker-based tools may identify a lower-risk acute graft-versus-host disease (GVHD) population amenable to novel, reduced-intensity…”
Get full text

Mutation Clearance after Transplantation for Myelodysplastic Syndrome by Duncavage, Eric J, Jacoby, Meagan A, Chang, Gue Su, Miller, Christopher A, Edwin, Natasha, Shao, Jin, Elliott, Kevin, Robinson, Joshua, Abel, Haley, Fulton, Robert S, Fronick, Catrina C, O’Laughlin, Michelle, Heath, Sharon E, Brendel, Kimberly, Saba, Raya, Wartman, Lukas D, Christopher, Matthew J, Pusic, Iskra, Welch, John S, Uy, Geoffrey L, Link, Daniel C, DiPersio, John F, Westervelt, Peter, Ley, Timothy J, Trinkaus, Kathryn, Graubert, Timothy A, Walter, Matthew J

“…The risk of disease progression among patients with myelodysplastic syndrome was higher among those in whom point mutations persisted in bone marrow at day 30…”
Get full text

Biomarker Panel for Chronic Graft-Versus-Host Disease by Yu, Jeffrey, Storer, Barry E, Kushekhar, Kushi, Abu Zaid, Mohammad, Zhang, Qing, Gafken, Philip R, Ogata, Yuko, Martin, Paul J, Flowers, Mary E, Hansen, John A, Arora, Mukta, Cutler, Corey, Jagasia, Madan, Pidala, Joseph, Hamilton, Betty K, Chen, George L, Pusic, Iskra, Lee, Stephanie J, Paczesny, Sophie

“…To identify diagnostic and prognostic markers of chronic graft-versus-host disease (cGVHD), the major cause of morbidity and mortality after allogeneic…”
Get full text

Engraftment of rare, pathogenic donor hematopoietic mutations in unrelated hematopoietic stem cell transplantation by Wong, Wing Hing, Bhatt, Sima, Trinkaus, Kathryn, Pusic, Iskra, Elliott, Kevin, Mahajan, Nitin, Wan, Fei, Switzer, Galen E, Confer, Dennis L, DiPersio, John, Pulsipher, Michael A, Shah, Nirali N, Sees, Jennifer, Bystry, Amelia, Blundell, Jamie R, Shaw, Bronwen E, Druley, Todd E

“…Clonal hematopoiesis is associated with various age-related morbidities. Error-corrected sequencing (ECS) of human blood samples, with a limit of detection of…”
Get more information

Patient-reported treatment response in chronic graft- versus -host disease by Im, Annie, Pusic, Iskra, Onstad, Lynn, Kitko, Carrie L, Hamilton, Betty K, Alousi, Amin M, Flowers, Mary E, Sarantopoulos, Stefanie, Carpenter, Paul, White, Jennifer, Arai, Sally, El Jurdi, Najla, Chen, George, Cutler, Corey, Lee, Stephanie, Pidala, Joseph

“…Chronic graft-versus-host disease (GvHD) treatment response is assessed using National Institutes of Health (NIH) Consensus Criteria in clinical trials, and by…”
Get full text

Predictors of survival, nonrelapse mortality, and failure-free survival in patients treated for chronic graft-versus-host disease by Palmer, Jeanne, Chai, Xiaoyu, Pidala, Joseph, Inamoto, Yoshihiro, Martin, Paul J., Storer, Barry, Pusic, Iskra, Flowers, Mary E.D., Arora, Mukta, Pavletic, Steven Z., Lee, Stephanie J.

“…Chronic graft-versus-host disease (GVHD) is a pleotropic syndrome that lacks validated methods of measuring response in clinical trials, although several end…”
Get full text

A Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis after Hematopoietic Cell Transplantation by Arai, Sally, Pidala, Joseph, Pusic, Iskra, Chai, Xiaoyu, Jaglowski, Samantha, Khera, Nandita, Palmer, Jeanne, Chen, George L, Jagasia, Madan H, Mayer, Sebastian A, Wood, William A, Green, Michael, Hyun, Teresa S, Inamoto, Yoshihiro, Storer, Barry E, Miklos, David B, Shulman, Howard M, Martin, Paul J, Sarantopoulos, Stefanie, Lee, Stephanie J, Flowers, Mary E D

“…Cutaneous sclerosis occurs in 20% of patients with chronic graft-versus-host disease (GVHD) and can compromise mobility and quality of life. We conducted a…”
Get full text

Lung Function Trajectory in Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Cell Transplant by Cheng, Guang-Shing, Storer, Barry, Chien, Jason W, Jagasia, Madan, Hubbard, Jesse J, Burns, Linda, Ho, Vincent T, Pidala, Joseph, Palmer, Jeanne, Johnston, Laura, Mayer, Sebastian, Crothers, Kristina, Pusic, Iskra, Lee, Stephanie J, Williams, Kirsten M

“…The natural history of lung function in patients with bronchiolitis obliterans syndrome (BOS) after allogeneic hematopoietic cell transplant is poorly…”
Get full text

A randomized phase 2 trial of pomalidomide in subjects failing prior therapy for chronic graft-versus-host disease by Curtis, Lauren M., Ostojic, Alen, Venzon, David J., Holtzman, Noa G., Pirsl, Filip, Kuzmina, Zoya J., Baird, Kristin, Rose, Jeremy J., Cowen, Edward W., Mays, Jacqueline W., Mitchell, Sandra A., Parsons-Wandell, Laura, Joe, Galen O., Comis, Leora E., Berger, Ann, Pusic, Iskra, Peer, Cody J., Figg, William D., Cao, Liang, Gale, Robert Peter, Hakim, Frances T., Pavletic, Steven Z.

“…Steroid-refractory chronic graft-versus-host disease (cGVHD) is a therapeutic challenge. Sclerotic skin manifestations are especially difficult to treat. We…”
Get full text

Selinexor combined with cladribine, cytarabine, and filgrastim in relapsed or refractory acute myeloid leukemia by Abboud, Ramzi, Chendamarai, Ezhilarasi, Rettig, Michael P, Trinkaus, Kathryn M, Riedell, Peter A, Abboud, Camille N, Ghobadi, Armin, Pusic, Iskra, Stockerl-Goldstein, Keith, Schroeder, Mark A, Vij, Ravi, Westervelt, Peter, DiPersio, John F, Uy, Geoffrey L

Get full text

Decitabine salvage for TP53 -mutated, relapsed/refractory acute myeloid leukemia after cytotoxic induction therapy by Ferraro, Francesca, Gruszczynska, Agata, Ruzinova, Marianna B, Miller, Christopher A, Percival, Mary Elizabeth, Uy, Geoffrey L, Pusic, Iskra, Jacoby, Meagan A, Christopher, Mathew J, Kim, Miriam Y, Westervelt, Peter, Cashen, Amanda F, Schroeder, Mark A, DiPersio, John F, Abboud, Camille N, Wartman, Lukas D, Gao, Feng, Link, Daniel C, Ley, Timothy J, Welch, John S

Get full text

How to utilize current guidelines to manage patients with cancer at high risk for heart failure by Bloom, Michelle, Alvarez-Cardona, Jose A, Ganatra, Sarju, Barac, Ana, Pusic, Iskra, Lenihan, Daniel, Dent, Susan

“…Heart failure (HF) in patients with cancer is associated with high morbidity and mortality. The success of cancer therapy has resulted in an exponential rise…”
Get full text

Measuring Therapeutic Response in Chronic Graft-versus-Host Disease. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2014 Response Criteria Working Group Report by Lee, Stephanie J, Wolff, Daniel, Kitko, Carrie, Koreth, John, Inamoto, Yoshihiro, Jagasia, Madan, Pidala, Joseph, Olivieri, Attilio, Martin, Paul J, Przepiorka, Donna, Pusic, Iskra, Dignan, Fiona, Mitchell, Sandra A, Lawitschka, Anita, Jacobsohn, David, Hall, Anne M, Flowers, Mary E.D, Schultz, Kirk R, Vogelsang, Georgia, Pavletic, Steven

“…Abstract In 2005, the National Institutes of Health (NIH) Chronic Graft-versus-Host Disease (GVHD) Consensus Response Criteria Working Group recommended…”
Get full text

National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2020 Etiology and Prevention Working Group Report by Williams, Kirsten M., Inamoto, Yoshihiro, Im, Annie, Hamilton, Betty, Koreth, John, Arora, Mukta, Pusic, Iskra, Mays, Jacqueline W., Carpenter, Paul A., Luznik, Leo, Reddy, Pavan, Ritz, Jerome, Greinix, Hildegard, Paczesny, Sophie, Blazar, Bruce R., Pidala, Joseph, Cutler, Corey, Wolff, Daniel, Schultz, Kirk R., Pavletic, Steven Z., Lee, Stephanie J., Martin, Paul J., Socie, Gerard, Sarantopoulos, Stefanie

“…Preventing chronic graft-versus-host disease (GVHD) remains challenging because the unique cellular and molecular pathways that incite chronic GVHD are poorly…”
Get full text

Challenges in Conducting Studies in Chronic Graft-versus-Host Disease by Pusic, Iskra, Pavletic, Steven Z.

“…The lack of standardized criteria for measuring therapeutic response has been a major obstacle to the development of therapeutic trials in chronic graft-…”
Get full text